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ABSTRACT 
Methadone (Met) mainly acts as a μ-opioid receptor agonist. Recent evidence pointing 
towards the role of Met in sensitization of certain cancer cell lines to chemotherapeutic 
agents has promoted the hypothesis that Met may be a useful adjuvant to cancer 
chemotherapy. We wanted to address whether Met has, alone or in combination with a 
chemotherapeutic agent, an effect on melanoma cell viability in vitro. Only a small fraction 
(4.3%) of our 102 melanoma biobank cell lines with RNA sequencing data showed 
expression of the main receptor for Met (OPRM1). We assessed the viability of melanoma 
cell lines with high, medium or low/no OPRM1 expression (OPRM1high, OPRM1med, 
OPRM1neg) 72 hours after treatment with Met alone or combined with cisplatin (Cis). Our 
analyses show that Met alone did not affect cell viability. While Cis/Met treatment did not 
have an effect on viability of OPRM1med or OPRM1neg cell lines, it resulted in a slightly 
decreased cell viability of OPRM1high cells. Clinically, concurrent temozolomide/Met 
treatment did not have an effect in our single-case report of a patient suffering from uveal 
melanoma. Taken together, our findings do not provide evidence for recommending Met as 
an adjuvant to chemotherapy in melanoma patients. 
 
BACKGROUND 
Methadone (D,L Methadone; Met) is a long-acting μ-opioid receptor (OPRM1) agonist (1). 
Met is mainly known and used as a heroine substitute, additional administration has been 
reported in the management of cancer pain (1).  
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A series of studies (2-9) has pointed towards an antitumoral effect of Met in various types of 
human cancer. In vitro data suggest that Met alone can induce apoptosis (5, 6), and, when 
combined with chemotherapeutic agents, sensitize cancer cells for their actions, possibly in 
an OPRM1-dependent fashion (8). Clinically, a retrospective, non placebo-controlled study 
has pointed towards a sensitizing role of Met for temozolomide (TMZ) chemotherapy in 
glioblastoma (9).  
 
These studies have recently received significant attention, resulting in numerous patient 
requests for Met. In melanoma, the potential for Met to sensitize patients for chemotherapy 
has not yet been addressed. 
 
QUESTIONS ADDRESSED 
We thus sought to investigate how the concept of Met as a sensitizer for chemotherapy 
translates to melanoma and may justify its clinical use. Our main aim was to evaluate 
whether in an in vitro setting, Met has, either alone or in combination with a 
chemotherapeutic agent, an effect on melanoma cell viability. The related questions were 
whether Met could 1) directly have an effect on the viability of melanoma cell lines and/or 2) 
indirectly sensitize melanoma cells to chemotherapeutic agents such as Cis.  
 
EXPERIMENTAL DESIGN 
Details on the subsequently described methods, cell lines and reagents are given in 
Supplementary Material and Methods. 
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Cell lines, Chemicals 
Patients gave their written informed consent approved by the local institutional review board 
(EK647/800). Primary melanoma cell cultures were established from metastatic melanoma 
tissue as previously described (10).  
 
Cell viability assay  
The cell lines were challenged with dose-escalating concentrations of Met alone, Cis alone, 
Cis/Met combined, an ERK-inhibitor or ERK-inhibitor/Met combined for 72 hours. Cell 
viability was estimated using a fluorometric (resazurin) assay.  
 
Immunohistochemistry stainings 
Immunohistochemical stainings were performed as previously described (11). We used an 
anti-OPRM1 antibody (PA5-26138; Thermo Fisher Scientific, Reinach, Switzerland), 
negative controls were obtained by substituting rabbit IgG for the primary antibody.  
 
RESULTS 
OPRM1 is lowly expressed in most melanoma cell lines 
Met binds to OPRM1, acting as an agonist . We first assess OPRM1 expression in 
melanoma based on RNAseq data from 102 cell lines of our URPP primary melanoma cell 
line biobank. Only four cell lines (4.3%) showed high (OPRM1high) and 58 (63%) medium 
OPRM1 (OPRM1med) expression, the other cell lines were OPRM1-negative (OPRM1neg). 
We chose an OPRM1high, OPRM1med and OPRM1neg melanoma cell line to test the effects of 
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Met (Figure 1A). Immunohistochemistry stainings confirmed the expression of OPRM1 at the 
protein level (Figure 1B). 
 
Met treatment does not significantly affect melanoma cell viability 
To investigate the effects of Met on these melanoma cell lines with regard to viability, we 
treated them with Met, Cis (positive control), medium (negative control) or a combination of 
Cis/Met using dose-escalating concentrations. A cell viability assay was performed after 72 
hours. In a series of three independent experiments, our results consistently showed that in 
OPRM1med and OPRM1neg melanoma cell lines, Met alone or in combination with Cis did not 
have any effect on cell viability (Figure 1C, D). In the OPRM1high melanoma cell line, we 
observed a slight decrease in cell viability (ranging from 10-20%) with Cis/Met as compared 
to Cis alone, but median dose effect (IC50) values were (when ANOVA one-way was 
applicable) not significantly different (Figure 1C). When using an ERK-inhibitor instead of 
Cis, we did not observe any synergistic effect of Met on cell viability (data not shown). 
 
Single-case study: metastatic uveal melanoma 
A 60 year-old patient with stage IV metastatic GNA11 mutant uveal melanoma (pTxN0M1c) 
showed progressive disease, i.e. new bone and extensive liver metastases following 4 
cycles of combined immunotherapy (ipilimumab 200mg, nivolumab 80mg). Previously, he 
had been treated with a pan-Raf-inhibitor and selective internal radiotherapy for his liver 
metastases. He was put on TMZ (200mg/m2 body surface area; 380mg daily per os, 5 
days/cycle). Concurrently to TMZ, Met was perscribed upon his request (10mg/ml, 30-0-30-0 
drops  daily per os). 
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Despite three cycles of TMZ/Met, he deteriorated clinically and was admitted to the hospital 
experiencing weight loss, asthenia, abdominal distension and peripheral edema. Lactate 
dehydrogenase levels had doubled (5017 U/l) and S-100 protein was elevated (0.45 ug/l). 
Computer tomography confirmed rapid disease progression in the liver with ascites and 
peritoneal carcinomatosis. The patient declined further melanoma-specific treatment and 
best supportive care was iniated. He died from liver failure two weeks upon admission.  
 
CONCLUSIONS 
Based on a series of studies (2-9) suggesting a role of Met as a chemotherapy sensitizer in 
certain cancer types, we addressed the potential/validity of this hypothesis in the setting of 
melanoma.  
 
Our results show high OPRM1 expression in only a minority of primary melanoma cultures 
obtained from patients with metastatic melanoma. Although we observed a slight decrease 
in cell viability (10-20%) in OPRM1high melanoma cells 72 hours after Cis/Met application (vs. 
Cis alone). Moreover, Cis/Met did not have any effect on OPRM1neg and OPRM1med 
melanoma cell lines. These in vitro findings indicate that 1) OPRM1 is expressed in a small 
subset of metastatic melanomas only and that 2) regardless of OPRM1 expression 
(neg/med/high), Met alone or in combination does not have a significant effect on melanoma 
cell viability.  
 
Whereas in various cancer types, OPRM1 expression has been associated with higher 
staging and/or poor outcome (8, 12-15), our findings suggest this is not the case in 
melanoma. As to the effects of Met, Friesen et al. (2-4) had reported that apoptosis rates 
increased by about 50% in leukemia and glioblastoma cell lines treated with Met combined 
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with chemotherapeutic agents. Importantly, Met concentration ranges (including therapeutic 
range) used by Friesen et al were covered in our experiments. The divergent results could, 
at least partially, be explained by the use of different cancer cell lines, but clearly show that 
Met does not have the potential to significantly impact cell viability in melanoma. Clinically, 
our single-case experience (concurrent treatment with TMZ/Met) showed a lack of effect in 
uveal melanoma.  
 
In conclusion, it seems unlikely that combining Met with chemotherapy has a beneficial 
effect for melanoma patients. Our findings do not provide evidence for recommending the 
use of Met as an adjuvant to chemotherapy to our melanoma patients.  
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FIGURE LEGENDS 
Figure 1.  
(A) Expression of OPRM1 (on the y axis, in log(counts per million) assessed by RNA 
sequencing in 102 melanoma cell lines  of our URPP biobank. Each dot corresponds to an 
individual melanoma cell line. The cell lines we chose for our experiments are highlighted 
(red frame), i.e. OPRM1neg (MM000921), OPRM1med (MM121008) and OPRM1high 
(MM141095). (B) Pictures of immunohistochemical OPRM1 staining of in the melanoma cell 
lines (OPRM1neg, OPRM1med and OPRM1high) we chose for our experiments. An isotype 
control and positive control (tonsil) are depicted in the left panel. (C) Changes in cell viability 
measured by a resazurin assay (results pooled from 3 independent experiments). Dose–
response curves for the melanoma cell lines (OPRM1neg, OPRM1med and OPRM1high) treated 
for 72 hours with Met, Cis or a combination of Met/Cis in a dose-escalating manner. Values 
are defined as means converted to percentages after normalization to untreated control; 
error bars represent SEM. (C) Median dose effect in nM (analogue of IC50) depicted for each 
melanoma cell line. 
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